Baidu
map

ACS Nano:前列腺癌特异性膜抗原靶标纳米金颗粒在前列腺癌中的诊断治疗

2018-04-18 AlexYang MedSci原创

前列腺癌是最常见的癌症抑制,并且在美国癌症死亡中占据主要地位。诊断患有前列腺癌的男性经典的是要经历根治性前列腺切除术,但该治疗方法经常导致尿失禁和阳痿。在大多数并没有完全切除的患者中,前列腺癌经常出现复发情况。因此,发展一项能够更加精细切除病灶的外科手术方法仍旧是一个挑战。最近,有研究人员报道了一种诊断治疗药物(AuNP-5kPEG-PSMA-1-Pc4),该药物基于前列腺特异性膜抗原为靶标的纳米

前列腺癌是最常见的癌症抑制,并且在美国癌症死亡中占据主要地位。诊断患有前列腺癌的男性经典的是要经历根治性前列腺切除术,但该治疗方法经常导致尿失禁和阳痿。在大多数并没有完全切除的患者中,前列腺癌经常出现复发情况。因此,发展一项能够更加精细切除病灶的外科手术方法仍旧是一个挑战。

最近,有研究人员报道了一种诊断治疗药物(AuNP-5kPEG-PSMA-1-Pc4),该药物基于前列腺特异性膜抗原为靶标的纳米金粒子(AuNPs),并在其上包裹荧光光动力治疗(PDT)药物-Pc4。组装的纳米粒子可以通过光谱和成像技术很好的进行鉴定,并且在许多溶剂、缓冲液和介质中都具有稳定性。研究发现,体外细胞摄入试验阐释了在PSMA阳性PC3pip细胞中要比对应的PSMA阴性PC3flu细胞中具有显著更多的纳米粒子摄入。更多的是,在不同的剂量光暴露条件下,在Pc3pip中杀伤的细胞要比PC3flu细胞更多,表明了Pc4传递后具有主动靶向特点。同样的,体内研究展示了PSMA表达肿瘤在PDT治疗14天后具有缓解效果。原子吸收光谱阐释了以AuNPs为靶标能够在PC2pip肿瘤中比PC3flu积累多4倍的纳米粒子。

最后,研究人员指出,当外科手术不能彻底治疗时,纳米粒子系统能够为前列腺肿瘤的切除提供手术指导和治疗诊断干预。

原始出处:

Mangadlao JD, Wang X, McCleese C et al. Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer. ACS Nano. 16 April 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1899210, encodeId=4774189921068, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Apr 21 08:02:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307841, encodeId=ed7230e84149, content=不错.学习了.做笔记了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sat Apr 21 08:00:55 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307629, encodeId=570230e629eb, content=谢谢提供, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55b4106607, createdName=holton, createdTime=Fri Apr 20 17:35:18 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279256, encodeId=29f312e925696, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352805, encodeId=b7e513528054b, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423637, encodeId=977a142363ed5, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623283, encodeId=96211623283ca, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1899210, encodeId=4774189921068, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Apr 21 08:02:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307841, encodeId=ed7230e84149, content=不错.学习了.做笔记了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sat Apr 21 08:00:55 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307629, encodeId=570230e629eb, content=谢谢提供, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55b4106607, createdName=holton, createdTime=Fri Apr 20 17:35:18 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279256, encodeId=29f312e925696, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352805, encodeId=b7e513528054b, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423637, encodeId=977a142363ed5, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623283, encodeId=96211623283ca, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
    2018-04-21 梦想起航ing

    不错.学习了.做笔记了.谢谢分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1899210, encodeId=4774189921068, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Apr 21 08:02:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307841, encodeId=ed7230e84149, content=不错.学习了.做笔记了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sat Apr 21 08:00:55 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307629, encodeId=570230e629eb, content=谢谢提供, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55b4106607, createdName=holton, createdTime=Fri Apr 20 17:35:18 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279256, encodeId=29f312e925696, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352805, encodeId=b7e513528054b, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423637, encodeId=977a142363ed5, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623283, encodeId=96211623283ca, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
    2018-04-20 holton

    谢谢提供

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1899210, encodeId=4774189921068, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Apr 21 08:02:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307841, encodeId=ed7230e84149, content=不错.学习了.做笔记了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sat Apr 21 08:00:55 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307629, encodeId=570230e629eb, content=谢谢提供, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55b4106607, createdName=holton, createdTime=Fri Apr 20 17:35:18 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279256, encodeId=29f312e925696, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352805, encodeId=b7e513528054b, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423637, encodeId=977a142363ed5, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623283, encodeId=96211623283ca, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
    2018-04-20 yaanren
  5. [GetPortalCommentsPageByObjectIdResponse(id=1899210, encodeId=4774189921068, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Apr 21 08:02:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307841, encodeId=ed7230e84149, content=不错.学习了.做笔记了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sat Apr 21 08:00:55 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307629, encodeId=570230e629eb, content=谢谢提供, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55b4106607, createdName=holton, createdTime=Fri Apr 20 17:35:18 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279256, encodeId=29f312e925696, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352805, encodeId=b7e513528054b, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423637, encodeId=977a142363ed5, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623283, encodeId=96211623283ca, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
    2018-04-20 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=1899210, encodeId=4774189921068, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Apr 21 08:02:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307841, encodeId=ed7230e84149, content=不错.学习了.做笔记了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sat Apr 21 08:00:55 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307629, encodeId=570230e629eb, content=谢谢提供, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55b4106607, createdName=holton, createdTime=Fri Apr 20 17:35:18 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279256, encodeId=29f312e925696, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352805, encodeId=b7e513528054b, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423637, encodeId=977a142363ed5, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623283, encodeId=96211623283ca, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1899210, encodeId=4774189921068, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Apr 21 08:02:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307841, encodeId=ed7230e84149, content=不错.学习了.做笔记了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sat Apr 21 08:00:55 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307629, encodeId=570230e629eb, content=谢谢提供, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55b4106607, createdName=holton, createdTime=Fri Apr 20 17:35:18 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279256, encodeId=29f312e925696, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352805, encodeId=b7e513528054b, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423637, encodeId=977a142363ed5, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623283, encodeId=96211623283ca, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Apr 20 11:02:00 CST 2018, time=2018-04-20, status=1, ipAttribution=)]

相关资讯

2018 GETUG建议:中度前列腺癌大分割放疗的剂量限制

2018年4月,法国泌尿生殖小组(GETUG)发布了中度前列腺癌大分割放疗的剂量限制建议,鉴于近期Ⅲ期试验结果,中度前列腺癌大分割放疗可作为低中风险前列腺癌的标准治疗方法,本文主要诊断中度前列腺癌大分割放疗的日常应用实践提供指导建议,考虑适应证,剂量,分级法,治疗前计划,剂量限制等。

Pathol Oncol Res:miR-146a, miR-196a2和miR-125a遗传多样性和与前列腺癌相关性研究

在印度人口中前列腺癌发生率的增加促使了易感人群和诊断所用的遗传标记的鉴定。之前的研究表明microRNA在致瘤过程中具有重要的作用,具体是通过改变增殖、分化和细胞死亡来发挥作用。基因的多样性,包括启动子区域和miRNA基因区域的多样性,都能够影响基因的表达。最近,有研究人员分析了miR-146a, miR-196a2和miR-125a在前列腺癌患者中的多样性情况。研究发现,在100个案例和100个

J Clin Oncol:兄弟间非低风险前列腺癌的一致性

最近,来自瑞典的研究人员进行了一项研究,调查了兄弟间非低风险前列腺癌的一致性如何受遗传关系的影响。

Clin Transl Oncol:microRNA-4319的重新表达能够抑制前列腺癌的生长

Her-2是一种表皮生长因子受体,并在一些前列腺癌(PC)中表达,且与肿瘤的外生长相关。一些microRNA的异常调节参与了PC发病机理的调控,然而miR-4319在PC中的角色仍旧未知。最近,有研究人员对miR-4319在PC中的作用进行了研究。研究人员通过RT-qPCR对miR-4319在PC组织中的水平进行了检测,并利用Kaplan-Meier分析调查了其表达水平与患者生存之间的相关性,并利

PLoS One:下尿路感染案例-对照以及相关抗生素和发展为前列腺癌风险的研究

最近,有研究人员进行了旨在调查下尿路感染与相关抗生素和随后发展为前列腺癌风险之间的相关性的研究。研究的数据来源于瑞典PCBaSe 3.0,研究人员进行的是相匹配的案例-对照研究(包括8762个案例和43806个对照)。研究发现,下尿路感染不影响前列腺癌风险。然而,与不具有下尿路感染的男性相比,具有下尿路感染或者在前列腺癌之前第一次使用抗生素6-12个月的均与前列腺癌风险的增加相关(分别为OR: 1

Cancers (Basel):中度和高风险前列腺癌原子射线治疗研究

原子射线治疗(PBT)作为局部前列腺癌(PCa)单一疗法,其在治疗中所起的具体作用仍旧不清楚。最近,有研究人员评估了这些局部前列腺癌(PCa)病人中,PBT单独治疗的效果和副作用。在2011年1月到2014年7月之间,共有218名患有中度到高风险PCa且拒绝雄激素阻断治疗(ADT)的病人被募集参与研究中,并且利用PBT进行治疗,且治疗方法遵从以下其中的一种:74 Gray(GyE)/37 frac

Baidu
map
Baidu
map
Baidu
map